APA (7th ed.) Citation

K, H., S, A. S., Y, S., O, S., A, A., M, M., . . . A, B. (2022). Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients. Clinical lymphoma, myeloma & leukemia, 22(8), 589. https://doi.org/10.1016/j.clml.2022.02.009

Chicago Style (17th ed.) Citation

K, Halahleh, et al. "Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients." Clinical Lymphoma, Myeloma & Leukemia 22, no. 8 (2022): 589. https://doi.org/10.1016/j.clml.2022.02.009.

MLA (9th ed.) Citation

K, Halahleh, et al. "Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients." Clinical Lymphoma, Myeloma & Leukemia, vol. 22, no. 8, 2022, p. 589, https://doi.org/10.1016/j.clml.2022.02.009.